Online first
Clinical vignette
Published online: 2024-06-21

open access

Page views 50
Article views/downloads 16
Get Citation

Connect on Social Media

Connect on Social Media

Complications of immunotherapy in the course of long-term response in a patient with non-small cell lung cancer

Anita S. Gorzelak-Magiera12, Małgorzata Domagała-Haduch12, Iwona Gisterek-Grocholska23

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Mok TSK, Wu YL, Kudaba I, et al. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183): 1819–1830.
  2. Wilky BA. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 2019; 290(1): 6–23.
  3. Cybulska-Stopa B, Czarnecka AM, Kamińska-Winciorek G, Rutkowski P. Bezpieczeństwo immunoterapii: zasady postępowania profilaktyczno-terapeutycznego w przypadku wystąpienia działań niepożądanych. Wyd. 2. Via Medica, Gdańsk 2022.
  4. Liu H, Li Y, Li J, et al. Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol. 2023; 14: 1199031.